A Safety and Efficacy Trial of TTHX1114 in People With CED — OPTIC

Corneal Endothelial Dystrophy Clinical Trial

Official title:
A Phase 2 Clinical Trial to Assess the Safety and Observe the Potential Benefit of TTHX1114 Delivered Via Intra-Cameral (IC) Injection

Status Completed

Clinical Trial Summary

Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Corneal Endothelial Dystrophy

Clinical Trial Details

NCT number	NCT04812067
Study type	Interventional
Source	Trefoil Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	November 30, 2021
Completion date	October 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05136443` - Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection	Phase 4
Recruiting	`NCT04191629` - Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema	Phase 1
Recruiting	`NCT03575130` - Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy	Phase 2
Active, not recruiting	`NCT04894110` - Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema	Phase 1
Recruiting	`NCT05636579` - Study to Assess Safety and Tolerability of Multiple Doses of EO2002	Phase 1
Completed	`NCT04520321` - A Phase 1/ Phase 2 Study of TTHX1114(NM141)	Phase 1/Phase 2